

Item 7.01 Regulation FD Disclosure.

On December 21, 2018, the U.S. Food and Drug Administration approved ULTOMIRIS™ (ravulizumab-cwvz), the first and only long-acting C5 complement inhibitor administered every eight weeks, for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating ultra-rare blood disorder characterized by complement-mediated hemolysis.

We have established a wholesale acquisition cost for ULTOMIRIS™ in the United States of \$6,404 per vial (30 mL of 10 mg/mL). On an annual basis, this represents an approximate 10% discount to the cost of current labeled maintenance therapy for adult PNH patients of average weight.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 21, 2018 ALEXION PHARMACEUTICALS, INC.

By: /s/ Douglas Barry_____

Name: Douglas Barry

Title: Vice President, Corporate Law